WeTrials
Completed

A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

What is this study?

This study is testing a new daily pill called orforglipron to see how well it works and if it is safe compared to a standard insulin injection called insulin glargine. It is designed for adults with type 2 diabetes who also carry extra weight and have a higher risk for heart issues.

Who can participate?

You may be able to join if you are an adult with type 2 diabetes who has overweight or obesity and has specific blood sugar levels. People with type 1 diabetes, active liver disease, or certain stomach and pancreas conditions cannot take part.

What will happen?

Over a period of about two years, participants will take either the study pill or the standard insulin and attend up to 27 check-in visits with the study team. Your health, blood sugar, and overall well-being will be closely monitored throughout this time.

Where and when?

This study has been completed and took place at various locations including Daphne, Mobile, and Pelham in Alabama, USA.

Key Points
  • 1Compares a new daily pill with a standard insulin injection
  • 2Focuses on adults with type 2 diabetes and extra body weight
  • 3Involves regular check-ins over about a two-year period

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Type 2 DiabetesObesityOverweight or ObesityOverweightCardiovascular DiseasesChronic Kidney Disease

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.